Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 131, Issue 6, Pages 355-363Publisher
SPRINGER
DOI: 10.1007/s00432-004-0653-9
Keywords
non-small cell lung cancer; multidrug resistance; P-glycoprotein; MRP1; LRP
Categories
Ask authors/readers for more resources
Purpose: The aim of this retrospective study was to comparatively investigate the expression of the three drug-resistance genes P-glycoprotein (P-gp), multidrug-resistance protein 1 (MRP1), and lung resistance protein (LRP), in non-small cell lung cancer (NSCLC) tissues, and to assess possible associations with clinicopathologic features. Methods: Tumor specimens from 126 patients were analyzed by immunohistochemistry and, in selected cases, by reverse transcriptase polymerase chain reaction (RT-PCR), and data were statistically analyzed by SPSS. Results: The mean expression levels of tumor tissues in the case of P-gp and LRP did not exceed the one of normal epithelia, while MRP1 was significantly enhanced in NSCLC. A weak association was observed between higher grading and P-glycoprotein expression (p < 0.08) as well as lower grading and MRP1 expression in the case of adenocarcinoma (p < 0.05). MRP1 levels were highest in TNM stage I and declined with advanced stage (p < 0.03). A significant association was found between high MRP1 levels and longer overall survival (N =115, p < 0.04), which was highly significant in the patient group never treated with chemotherapy (N =77; p < 0.007). P-gp expression was enhanced in those patients who had received chemotherapy before surgery ( p < 0.05). Conclusions: Our data point towards a major role of MRP1 in the intrinsic treatment resistance of NSCLC and suggest, in addition, a significant activation of P-gp expression during chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available